(0.19%) 5 141.00 points
(0.16%) 38 504 points
(0.26%) 17 892 points
(-0.87%) $83.12
(1.61%) $1.954
(-0.17%) $2 343.20
(0.89%) $27.50
(0.25%) $924.40
(-0.18%) $0.933
(-0.13%) $11.01
(-0.24%) $0.798
(1.18%) $92.96
Live Chart Being Loaded With Signals
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States...
Stats | |
---|---|
本日の出来高 | 6 759.00 |
平均出来高 | 15 388.00 |
時価総額 | 7.45M |
EPS | $-0.570 ( 2024-04-04 ) |
次の収益日 | ( $-1.040 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.530 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-26 | Siegert Michelle | Buy | 9 900 | Stock Option (Right to Buy) |
2023-01-26 | Wasilewski Margaret | Buy | 11 400 | Stock Option (Right to Buy) |
2023-01-26 | Raad Teofilo David | Buy | 34 900 | Stock Option (Right to Buy) |
2023-01-26 | Bazemore Todd | Buy | 1 700 | Stock Option (Right to Buy) |
2023-01-26 | Higgins Michael J | Buy | 2 436 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 13 676 591 | Sell: 104 308 |
Pulmatrix Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Pulmatrix Inc 財務諸表
Annual | 2023 |
収益: | $7.30M |
総利益: | $5.82M (79.79 %) |
EPS: | $-3.87 |
FY | 2023 |
収益: | $7.30M |
総利益: | $5.82M (79.79 %) |
EPS: | $-3.87 |
FY | 2022 |
収益: | $6.07M |
総利益: | $4.53M (74.55 %) |
EPS: | $-5.43 |
FY | 2021 |
収益: | $5 169.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.00745 |
Financial Reports:
No articles found.
Pulmatrix Inc
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。